Precision oncology only works when biomarker testing helps identify the right patients before launch, explains Boehringer ...

Nasdaq’s new $5 million MVLS rule raises delisting risk for micro-cap life sciences companies, making exchange choice an ...

Patrick Mooney, CEO of SpyGlass Pharma, shares how insights from the cockpit have shaped his approach to leading an innovative biotech.

Life Sciences M&A policies in the EU, Israel, and Singapore are shifting, creating new opportunities for drug developers, according to legal experts at Meritas.

On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, ...

Biotech’s old risk-sharing model is breaking down, forcing academia, investors, pharma, and healthcare systems to collaborate earlier to bring cures to patients.

As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large ...

A substantial share of biopharmaceutical drug launches (>50%) fail to meet their projected analyst forecasts (see also Simon-Kucher Biotech industry study 2019). With considerable investment going ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

Artificial intelligence is revolutionizing the life sciences industry by driving innovation in various domains, such as drug discovery, clinical trials, and regulatory compliance. While AI offers the ...

IN 2017, SAQIB ISLAM FOUND HIMSELF FACING ONE OF THOSE PIVOTAL CAREER DECISIONS — LEAVE A GOOD JOB AT A GOOD COMPANY FOR THE CHANCE TO GROW A FLEDGLING STARTUP. He was only a year into his job as ...